Jul 15, 2019- U.S. approval for MitraClip G4 offers a next-generation approach to mitral valve repair- G4 includes new clip sizes and an enhanced leaflet grasping feature- May 21, 2019- Late-breaking data for Abbott's investigational clip-based tricuspid heart valve repair system presented at EuroPCR- Data suggest the first-of-its-kind device reduces difficult-to-treat tricuspid regurgitation at 30 days- Study builds upon Abbott's success with its proven MitraClip™ clip-based technology in treating a similar disease on the left side of the heart
- May 14, 2019- Partnership with NIH aims to increase understanding and accelerate the application of neurostimulation therapies- The BRAIN Initiative brings together the brightest minds across disciplines to improve the treatment and prevention of brain disorders
- Apr 29, 2019- Research found Abbott's High-Sensitive Troponin-I blood test may identify adults at risk of having a cardiac event, independent of other heart disease risk factors- Abbott's core laboratory diagnostic test is the first troponin blood test with CE Mark that can more accurately predict risk of developing heart disease, when added to other heart disease risk assessments, than using other assessments alone
- Mar 14, 2019- The world's first minimally invasive mitral valve repair device now approved to help difficult-to-treat heart failure patients with clinically significant secondary mitral regurgitation- Approval is based on groundbreaking pivotal data from the COAPT™ Trial- New indication significantly expands number of people with mitral regurgitation that can be treated with the MitraClip device
- Feb 20, 2019Collaboration will enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible(i) with FreeStyle Libre portfolio of products
- Jan 21, 2019With approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, Abbott is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation
-
Jan 19, 2019- Data from two recent studies presented at NANS 2019 demonstrate key benefits of BurstDR™ stimulation- Microdosing BurstDR stimulation at lowest effective energy allows patients to manage their pain without the burden of recharging their devices- Additional data further showed switching from other types of SCS therapies to Abbott’s BurstDR stimulation significantly reduced pain and the need for opioid medication